FilingReader Intelligence
Kaken Pharmaceutical raises sales forecast amid licensing deals
April 8, 2025 at 12:01 PM UTC•By FilingReader AI
Kaken Pharmaceutical (TSE:4521) announced an upward revision to its consolidated sales forecast for the fiscal year ending March 31, 2025, driven primarily by upfront payments from recently secured licensing agreements. The company now projects net sales of JPY94,000 million, a 6.2% increase from the previous forecast of JPY88,500 million announced on August 7, 2024.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
TSE:4521•Tokyo Stock Exchange
News Alerts
Get instant email alerts when Kaken Pharmaceutical publishes news
Free account required • Unsubscribe anytime